I
Incisive Genetics
Developing its innovative lipid nanoparticle (lnp) delivery platform for genetic therapies
About Incisive Genetics
Incisive Genetics Inc. is a privately held biotech company specializing in the research and development of a novel non-viral delivery platform for targeted CRISPR-based gene therapies. The company operates in the genetic medicine market, focusing on precision medicine solutions that aim to treat genetic disorders at their root cause. Incisive Genetics serves clients in the healthcare and pharmaceutical sectors, including research institutions and biotech firms looking for advanced gene editing solutions. The business model revolves around developing and licensing its proprietary Incisive Delivery technology, which is designed to improve the efficiency and safety of gene editing therapies. Revenue is generated through partnerships, licensing agreements, and research grants. The company recently raised 12 million CAD in an expanded seed round, demonstrating strong investor confidence in its innovative approach.
Source: Dealroom company dataAt a glance
- Founded
- 2018
- Headquarters
- Vancouver, Canada
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
- HFHaig Farris
NOEL HALL- SMSandra MacPherson
- RORobinson Sauder Family Office
Velocity Capital Management
Saltagen Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Incisive Genetics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Incisive Genetics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.